Data Insights

Risk adjusted net present value: What is the current valuation of Regeneron Pharmaceuticals's Fianlimab?

Fianlimab is a monoclonal antibody commercialized by Regeneron Pharmaceuticals, with a leading Phase III program in Squamous Non-Small Cell Lung...

Net Present Value Model: Regeneron Pharmaceuticals Inc's Fianlimab

Data Insights

Fianlimab by Regeneron Pharmaceuticals for Lung Cancer: Likelihood of Approval

Fianlimab is under clinical development by Regeneron Pharmaceuticals and currently in Phase I for Lung Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Fianlimab in Lung Cancer

Data Insights

Fianlimab by Regeneron Pharmaceuticals for Lymphoma: Likelihood of Approval

Fianlimab is under clinical development by Regeneron Pharmaceuticals and currently in Phase I for Lymphoma. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Fianlimab in Lymphoma

Data Insights

Fianlimab by Regeneron Pharmaceuticals for Advanced Malignancy: Likelihood of Approval

Fianlimab is under clinical development by Regeneron Pharmaceuticals and currently in Phase I for Advanced Malignancy. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Fianlimab in Advanced Malignancy

Data Insights

Fianlimab by Regeneron Pharmaceuticals for Solid Tumor: Likelihood of Approval

Fianlimab is under clinical development by Regeneron Pharmaceuticals and currently in Phase I for Solid Tumor. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Fianlimab in Solid Tumor

Data Insights

Fianlimab by Regeneron Pharmaceuticals for Thyroid Cancer: Likelihood of Approval

Fianlimab is under clinical development by Regeneron Pharmaceuticals and currently in Phase I for Thyroid Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Fianlimab in Thyroid Cancer

Data Insights

Fianlimab by Regeneron Pharmaceuticals for Hematological Tumor: Likelihood of Approval

Fianlimab is under clinical development by Regeneron Pharmaceuticals and currently in Phase I for Hematological Tumor. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Fianlimab in Hematological Tumor

Data Insights

Fianlimab by Regeneron Pharmaceuticals for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

Fianlimab is under clinical development by Regeneron Pharmaceuticals and currently in Phase I for Head And Neck Squamous Cell Carcinoma...

Likelihood of Approval and Phase Transition Success Rate Model - Fianlimab in Head And Neck Squamous Cell Carcinoma (HNSC)